FUSION PROTEINS FOR APPLICATION AS IMMUNOGENIC AMPLIFYING AGENTS TO INDUCE ANTIGEN-SPECIFIC T-CELL RESPONSE Russian patent published in 2017 - IPC C07K19/00 C07K14/05 C07K14/705 C07K14/81 C12N5/783 A61K39/00 A61K39/385 A61P37/00 

FIELD: biotechnology.

SUBSTANCE: fusion protein having (a) a binding domain with AIC or a binding domain with a CD91 receptor located at the N-terminus of a fusion protein, (b) a translocation peptide of 34 to 112 amino acid residues located at the C-terminus of the binding domain with AIC or binding domain with the CD91 receptor; (c) a pathogen antigen; (d) a nuclear export signal and (e) a sequence providing retention in the endoplasmic reticulum located at the C-terminus of the fusion protein, where the nuclear export signal is between the antigen and the sequence providing retention in the endoplasmic reticulum, or between the translocation peptide and the antigen.

EFFECT: proposed invention allows induction of enhanced antigen-specific T-cell responses against a pathogen selected from HPV, PRRSV, HIV-1, Dengue virus, HCV, HBV, PCV2, CSFV, FMDV, NDV, TGEV, PEDV, influenza virus, pseudorabies virus , parvovirus, SVDV, smallpox virus, rotavirus, Mycoplasma pneumonia, herpes virus, infectious bronchitis virus or infectious bursitis virus.

20 cl, 8 dwg, 1 tbl, 8 ex